Similar articles for PMID: 12353320

Year	Number of Results
1950	1
1968	1
1976	1
1977	1
1993	1
2001	4
2002	10
2003	16
2004	7
2005	12
2006	12
2007	18
2008	12
2009	11
2010	7
2011	12
2012	8
2013	7
2014	8
2015	2
2016	4
2017	3
2018	3
2020	1
2021	1
2024	0

1

Cardiac tamponade associated with imatinib mesylate therapy of chronic myelogenous leukemia.

Barton JC, Jones SC, Lamberth WC, Reymann MT, Scott VC. Barton JC, et al. Am J Hematol. 2002 Oct;71(2):139-40. doi: 10.1002/ajh.10186. Am J Hematol. 2002. PMID: 12353320 Free article. No abstract available.

2

A case of chronic myeloid leukemia with eosinophilic interstitial pneumonitis after administration of imatinib mesylate for 11 months.

Suemori K, Fujiwara H, Watanabe S, Azuma T, Yasukawa M. Suemori K, et al. Int J Hematol. 2010 Dec;92(5):777-8. doi: 10.1007/s12185-010-0729-z. Epub 2010 Nov 26. Int J Hematol. 2010. PMID: 21110146 No abstract available.

3

Imatinib mesylate: a new pill for chronic myelogenous leukemia.

Parmar KK, King RS. Parmar KK, et al. Cancer Pract. 2001 Sep-Oct;9(5):263-5. doi: 10.1046/j.1523-5394.2001.95003.x. Cancer Pract. 2001. PMID: 11879324 No abstract available.

4

Successful management of liver injury caused by imatinib mesylate in a patient with previously untreated chronic myelogenous leukemia in the chronic phase.

Yamazaki R, Okamoto S, Chen CK, Tada S, Saito H, Shibata R, Sakamoto M, Mori T, Ikeda Y. Yamazaki R, et al. Leuk Lymphoma. 2006 Jul;47(7):1427-30. doi: 10.1080/10428190600593877. Leuk Lymphoma. 2006. PMID: 16923586 No abstract available.

5

Thrombocytopenia induced by imatinib mesylate (Glivec) in patients with chronic myelogenous leukemia: is 400 mg daily of imatinib mesylate an optimal starting dose for Japanese patients?

Miyazawa K, Nishimaki J, Katagiri T, Sashida G, Shoji N, Kawakubo K, Suzuki A, Shimamoto T, Gotoh A, Kuriyama Y, Ito Y, Tauchi T, Kawanishi Y, Kimura Y, Ohyashiki K. Miyazawa K, et al. Int J Hematol. 2003 Jan;77(1):93-5. doi: 10.1007/BF02982610. Int J Hematol. 2003. PMID: 12568307 No abstract available.

6

Imatinib mesylate induced immune thrombocytopenia.

Rajappa S, Varadpande L, Paul TR, Digumarti R. Rajappa S, et al. Leuk Lymphoma. 2007 Nov;48(11):2261-3. doi: 10.1080/10428190701615934. Leuk Lymphoma. 2007. PMID: 17926182 No abstract available.

7

Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate.

Rousselot P, Larghero J, Raffoux E, Calvo F, Tulliez M, Giraudier S, Rybojad M. Rousselot P, et al. Br J Haematol. 2003 Mar;120(6):1091-2. doi: 10.1046/j.1365-2141.2003.04208_3.x. Br J Haematol. 2003. PMID: 12648085 Free article. No abstract available.

8

Pleural-pericardic effusion as uncommon complication in CML patients treated with Imatinib.

Breccia M, D'Elia GM, D'Andrea M, Latagliata R, Alimena G. Breccia M, et al. Eur J Haematol. 2005 Jan;74(1):89-90. doi: 10.1111/j.1600-0609.2004.00347.x. Eur J Haematol. 2005. PMID: 15613116 No abstract available.

9

Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate.

Arora B, Kumar L, Sharma A, Wadhwa J, Kochupillai V. Arora B, et al. Ann Oncol. 2004 Feb;15(2):358-9. doi: 10.1093/annonc/mdh068. Ann Oncol. 2004. PMID: 14760137 Free article. Clinical Trial. No abstract available.

10

Unusual fluid retention with imatinib therapy for chronic myeloid leukemia.

Ostro D, Lipton J. Ostro D, et al. Leuk Lymphoma. 2007 Jan;48(1):195-6. doi: 10.1080/10428190600923157. Leuk Lymphoma. 2007. PMID: 17325868 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

152 results

Results by year